Ventricular Tachycardia in Anteroseptal STEMI
Case Report
DOI:
https://doi.org/10.55175/cdk.v52i8.1345Keywords:
STEMI, sudden cardiac death, ventricular tachycardiaAbstract
Introduction: Fatal ventricular tachyarrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF) are the most frequent cause of sudden cardiac death. In-hospital mortality of VT in STEMI was a 4- to 5-fold increase compared to STEMI without ventricular tachyarrhythmia; VT and VF were also initially thought to be the most common causes of out-of-hospital cardiac arrest. Late VT (occurs beyond 24-48 hours of STEMI onset) is a predictor for worse prognosis. Case: A 49-year-old female presented with continuous chest pain for 5 days and a rapid heartbeat (palpitation) for 4 days before hospital admission. Initial examination revealed VT and ST elevation on ECG, leading to a diagnosis of anteroseptal STEMI with VT. Treatment included aspirin, clopidogrel, heparin, isosorbide dinitrate, bisoprolol, and simvastatin. The VT resolved about 2 hours after the initial treatment, and the evolution of STEMI (on ECG) was observed. Conclusion: Early recognition and prompt treatment for VT patients can prevent hemodynamic instability and reduce mortality.
Downloads
References
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset kesehatan dasar (RISKESDAS). Jakarta; 2018.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 2022;145(8):E153–639. doi: 10.1161/CIR.0000000000001052.
Dharma S, Siswanto BB, Firdaus I, Dakota I, Andriantoro H, Wardeh AJ, et al. Temporal trends of system of care for STEMI: insights from the Jakarta cardiovascular care unit network system. PLoS One 2014;9(2):1–5. doi: 10.1371/journal.pone.0086665.
Foth C, Gangwani MK, Ahmed I, Alvey H. Ventricular tachycardia [Internet]. StatPearls Publishing; 2023 Feb 27 [cited 2023 Jul 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532954/.
Amoni M, Dries E, Ingelaere S, Vermoortele D, Roderick HL, Claus P, et al. Ventricular arrhythmias in ischemic cardiomyopathy—new avenues for mechanism-guided treatment. Cells 2021;10:1–29. doi: 10.3390/cells10102629.
Philip J Podrid MF. Ventricular arrhythmias during acute myocardial infarction: incidence, mechanisms, and clinical features [Internet]. UpToDate; 2022. [cited 2023 Jul 11]. Available from: https://medilib.ir/uptodate/show/1060.
Daindes T, Rasyid H El. Ventrikular takikardia refrakter pada STEMI & stroke. J Kes Andalas. 2018;7:111-5. doi: https://doi.org/10.25077/jka.v7i0.861.
AlKalbani A, AlRawahi N. Management of monomorphic ventricular tachycardia electrical storm in structural heart disease. J Saudi Heart Assoc. 2019;31:135–44. doi: 10.1016/j.jsha.2019.05.001.
Sattler SM, Skibsbye L, Linz D, Lubberding AF, Tfelt-Hansen J, Jespersen T. Ventricular arrhythmias in first acute myocardial infarction: epidemiology, mechanisms, and interventions in large animal models. Front Cardiovasc Med. 2019;6:158. doi: 10.3389/fcvm.2019.00158.
Yow AG, Rajasurya V, Sharma S. Sudden cardiac death [Internet]. StatPearls Publishing; 2022 Aug 8 [cited 2023 Jul 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507854/
Demidova MM, Rylance R, Koul S, Dworeck C, James S, Aasa M, et al. Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a substudy of VALIDATE-SWEDEHEART trial. Heart Rhythm O2. 2023;4(3):200–6. doi: 10.1016/j.hroo.2022.12.008.
Okninska M, Mączewski M, Mackiewicz U. Ventricular arrhythmias in acute myocardial ischaemia—focus on the ageing and sex. Ageing Res Rev. 2022;81:101722. doi: 10.1016/j.arr.2022.101722.
Thomas DE, Jex N, Thornley AR, Thornley CA. Ventricular arrhythmias in acute coronary syndromes—mechanisms and management. Wiley Online Library 2017;3(1):22–9. doi: 10.1002/cce2.51.
Woie L, Eftestol T, Engan K, Kvaloy JT, Nilsen DWT, Orn S. The heart rate of ventricular tachycardia following an old myocardial infarction is inversely related to the size of scarring. Europace 2011;13(6):864–8. doi: 10.1093/europace/euq466.
Thomsen AF, Jons C, Jabbari R, Jacobsen MR, Stampe NK, Butt JH, et al. Long-term risk of new-onset arrhythmia in ST-segment elevation myocardial infarction according to revascularization status. Europace 2023;25(3):931-9. doi: 10.1093/europace/euac242.
Onwordi ENC, Gamal A, Zaman A. Anticoagulant therapy for acute coronary syndromes. Interventional Cardiology Review 2018;13(2):87. doi: 10.15420/icr.2017:26:1.
McGinley C, Mordi IR, Kelly P, Currie P, Hutcheon S, Koch S, et al. Prehospital administration of unfractionated heparin in ST-segment elevation myocardial infarction is associated with improved long-term survival. J Cardiovasc Pharmacol. 2020;76(2):159–63. doi: 10.1097/FJC.0000000000000865.
Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. NEJM. [Internet]. 2015;373(11):997–1009. doi: 10.1056/NEJMoa1507854.
Zuo G, Li Y, Hu S, Wang K, Zhao H, Wang D, et al. The efficacy of the use of heparin in the emergency room in patients with acute ST-segment elevation myocardial infarction. J Radiat Res Appl Sci. 2022;15(1):187–92. doi:10.1016/j.jrras.2022.03.002.
Cohen M, Boiangiu C, Abidi M. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. J Am Coll Cardiol. 2010;55(18):1895–906. doi: 10.1016/j.jacc.2009.11.087.
Agushi E, Pizzi C, Cenko E, Carnevale R, Santarella L, Bugiardini R. Unfractionated heparin/clopidogrel interaction in patients with STEMI not undergoing reperfusion. J Am Coll Cardiol. 2013;61(10):E136.
Bugiardini R, Dorobantu M, Vasiljevic Z, Kedev S, Knezevic B, Milicic D, et al. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. Atherosclerosis 2015;241(1):151–6. doi: 10.1016/j.atherosclerosis.2015.04.794.
Wolowiec L, Grzesk G, Osiak J, Wijata A, Medlewska M, Gaborek P, et al. Beta-blockers in cardiac arrhythmias–clinical pharmacologist’s point of view. Front Pharmacol. 2022;13:1043714. doi: 10.3389/fphar.2022.1043714.
Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915–21. doi: 10.1016/j.ijcard.2012.10.050.
Hirschl MM, Wollmann CG, Erhart F, Brunner W, Pfeffel F, Gattermeier M, et al. Benefit of immediate beta-blocker therapy on mortality in patients with ST-segment elevation myocardial infarction. Crit Care Med. 2013;41(6):1396–404. doi: 10.1097/CCM.0b013e31827caa64.
Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology’s NCDR®. Am Heart J. 2011;161(5):864–70. doi: 10.1016/j.ahj.2011.01.006.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Bloma N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867. doi: 10.1093/eurheartj/ehv316.
Schupp T, Behnes M, Weiß C, Nienaber C, Lang S, Reiser L, et al. Beta-blockers and ACE inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia. Cardiovasc Drugs Ther. 2018;32(4):353–63. doi: 10.1007/s10557-018-6812-z.
Larson J, Rich L, Deshmukh A, Judge EC, Liang JJ. Pharmacologic management for ventricular arrhythmias: overview of anti-arrhythmic drugs. J Clin Med 2022;11:3233. doi: 10.3390/jcm11113233.
Van Herendael H, Dorian P, Michael S. Vascular health and risk management dovepress amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia [Internet]. Dovepress; 2010. Available from: www.dovepress.com.
Schupp T, Behnes M, Reiser L, Bollow A, Taton G, Reichelt T, et al. Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. Int J Cardiol. 2019 Feb 15;277:118–24. doi: 10.1016/j.ijcard.2018.11.030.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Luzelia Marta Sequeira Saldanha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
